Category: 120258-69-7

New Advances in Chemical Research, May 2021. The dynamic chemical diversity of the numerous elements, ions and molecules that constitute the basis of life provides wide challenges and opportunities for research. Application of 120258-69-7, We’ll be discussing some of the latest developments in chemical about CAS: 120258-69-7, name is 2,8-Dichloroquinoxaline. In an article，Which mentioned a new discovery about 120258-69-7

This invention provides certain sulfonamidoquinoxaline derivatives and methods for using them in the treatment of susceptible neoplasms in mammals. Also provided are certain novel pharmaceutical formulations employing these sulfonamidoquinoxaline derivatives, in combination with a carrier, diluent or excipient.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Application of 120258-69-7. In my other articles, you can also check out more blogs about 120258-69-7

Reference：
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1687 | ChemSpider

New Advances in Chemical Research, May 2021. In heterogeneous catalysis, the catalyst is in a different phase from the reactants. Formula: C8H4Cl2N2, We’ll be discussing some of the latest developments in chemical about CAS: 120258-69-7, name is 2,8-Dichloroquinoxaline. In an article，Which mentioned a new discovery about 120258-69-7

2-{4-[(7-Chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid (XK469) is among the most highly and broadly active antitumor agents to have been evaluated in our laboratories and is currently scheduled to enter clinical trials in 2001. The mechanism or mechanisms of action of XK469 remain to be elaborated. Accordingly, an effort was initiated to establish a pharmacophore hypothesis to delineate the requirements of the active site, via a comprehensive program of synthesis of analogues of XK469 and evaluation of the effects of structural modification(s) on solid tumor activity. The strategy formulated chose to dissect the two-dimensional parent structure into three regions – I, ring A of quinoxaline; II, the hydroquinone connector linkage; and III, the lactic acid moiety – to determine the resultant in vitro and in vivo effects of chemical alterations in each region. Neither the A-ring unsubstituted nor the B-ring 3-chloro-regioisomer of XK469 showed antitumor activity. The modulating antitumor effect(s) of substituents of differing electronegativities, located at the several sites comprising the A-ring of region I, were next ascertained. Thus, a halogen substituent, located at the 7-position of a 2-{4-[(2-quinoxalinyl)oxy]phenoxy}propionic acid, generated the most highly and broadly active antitumor agents. A methyl, methoxy, or an azido substituent at this site generated a much less active structure, whereas 5-, 6-, 8-chloro-, 6-, 7-nitro, and 7-amino derivatives all proved to be essentially inactive. When the connector linkage (region II) of 1 was changed from that of a hydroquinone to either a resorcinol or a catechol derivative, all antitumor activity was lost. Of the carboxylic acid derivatives of XK469 (region III), i.e., CONH2, CONHCH3, CON(CH3)2, CONHOH, CONHNH2, CN, or CN4H (tetrazole), only the monomethyl- and N,N-dimethylamides proved to be active.

We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 120258-69-7, and how the biochemistry of the body works.Formula: C8H4Cl2N2

Reference：
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1688 | ChemSpider

Formula: C8H4Cl2N2, New research progress on 120258-69-7 in 2021. In classical electrochemical theory, both the electron transfer rate and the adsorption of reactants at the electrode control the electrochemical reaction. 120258-69-7, Name is 2,8-Dichloroquinoxaline, molecular formula is C8H4Cl2N2. In a Patent，once mentioned of 120258-69-7

The invention relates to compounds o f formula (1), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pirn kinase related conditions and diseases, preferably cancer.

Do you like my blog? If you like, you can also browse other articles about this kind. Thanks for taking the time to read the blog about 120258-69-7

Reference：
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1686 | ChemSpider

Reference of 120258-69-7, Chemistry is the science of change. But why do chemical reactions take place? Why do chemicals react with each other? The answer is in thermodynamics and kinetics.In a document type is Patent, and a compound is mentioned, 120258-69-7, 2,8-Dichloroquinoxaline, introducing its new discovery.

This invention provides certain sulfonamidoquinoxaline derivatives and methods for using them in the treatment of susceptible neoplasms in mammals. Also provided are certain novel pharmaceutical formulations employing these sulfonamidoquinoxaline derivatives, in combination with a carrier, diluent or excipient.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Reference of 120258-69-7. In my other articles, you can also check out more blogs about 120258-69-7

Reference：
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1687 | ChemSpider

In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 120258-69-7, name is 2,8-Dichloroquinoxaline, introducing its new discovery. Computed Properties of C8H4Cl2N2

Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid (XK469)

2-{4-[(7-Chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid (XK469) is among the most highly and broadly active antitumor agents to have been evaluated in our laboratories and is currently scheduled to enter clinical trials in 2001. The mechanism or mechanisms of action of XK469 remain to be elaborated. Accordingly, an effort was initiated to establish a pharmacophore hypothesis to delineate the requirements of the active site, via a comprehensive program of synthesis of analogues of XK469 and evaluation of the effects of structural modification(s) on solid tumor activity. The strategy formulated chose to dissect the two-dimensional parent structure into three regions – I, ring A of quinoxaline; II, the hydroquinone connector linkage; and III, the lactic acid moiety – to determine the resultant in vitro and in vivo effects of chemical alterations in each region. Neither the A-ring unsubstituted nor the B-ring 3-chloro-regioisomer of XK469 showed antitumor activity. The modulating antitumor effect(s) of substituents of differing electronegativities, located at the several sites comprising the A-ring of region I, were next ascertained. Thus, a halogen substituent, located at the 7-position of a 2-{4-[(2-quinoxalinyl)oxy]phenoxy}propionic acid, generated the most highly and broadly active antitumor agents. A methyl, methoxy, or an azido substituent at this site generated a much less active structure, whereas 5-, 6-, 8-chloro-, 6-, 7-nitro, and 7-amino derivatives all proved to be essentially inactive. When the connector linkage (region II) of 1 was changed from that of a hydroquinone to either a resorcinol or a catechol derivative, all antitumor activity was lost. Of the carboxylic acid derivatives of XK469 (region III), i.e., CONH2, CONHCH3, CON(CH3)2, CONHOH, CONHNH2, CN, or CN4H (tetrazole), only the monomethyl- and N,N-dimethylamides proved to be active.

We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 120258-69-7, and how the biochemistry of the body works.Computed Properties of C8H4Cl2N2

Reference£º
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1688 | ChemSpider

120258-69-7, Name is 2,8-Dichloroquinoxaline, belongs to quinoxaline compound, is a common compound. name: 2,8-DichloroquinoxalineIn an article, once mentioned the new application about 120258-69-7.

MACROCYCLES AS PIM INHIBITORS

The invention relates to compounds o f formula (1), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pirn kinase related conditions and diseases, preferably cancer.

Do you like my blog? If you like, you can also browse other articles about this kind. Thanks for taking the time to read the blog about 120258-69-7

Reference£º
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1686 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.120258-69-7,2,8-Dichloroquinoxaline,as a common compound, the synthetic route is as follows.

2,8-Dichloroquinoxaline (Pharmabridge Inc., Doylestown, PA; 2.00 g, 10.05 mmol) and 2-methylallylamine (Matrix, Columbia, SC; 4.29 ml, 60.3 mmol) were combined in a tube, sealed, and heated to 80 C in an oil bath. After 4 h, the reaction was cooled and the reaction was partitioned between saturated aqueous NaHC03 and DCM. The aqueous layer was extracted with DCM 3 times, and the combined organics were dried over anhydrous Na2S04, filtered, and concentrated in vacuo to give 8-chloro-N-(2- methylallyl)quinoxalin-2 -amine (2.40 g, 10.27 mmol, quantitative yield) as an orange semi-solid: FontWeight=”Bold” FontSize=”10″ H NMR (400 MHz, CDCl3) delta ppm 8.28 (1 H, s), 7.77 – 7.85 (1 H, m), 7.69 (1 H, d, J=7.7 Hz), 7.29 – 7.34 (1 H, m), 5.04 (1 H, s), 4.96 (1 H, s), 4.20 (2 H, d, J=5.9 Hz), 1.87 (3 H, s). m/z (ESI, +ve) 234.1 (M+H)+.

120258-69-7, As the paragraph descriping shows that 120258-69-7 is playing an increasingly important role.

Reference£º
Patent; AMGEN INC.; CEE, Victor J.; BROWN, James; CHAVEZ JR., Frank; CHEN, Jian J.; HERBERICH, Bradley J.; HARRINGTON, Essa Hu; LANMAN, Brian Alan; LEE, Matthew; PETTUS, Liping H.; REED, Anthony B.; TASKER, Andrew; WANG, Hui-Ling; WU, Bin; WURZ, Ryan; WO2014/22752; (2014); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider